Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases.
The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.
In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines.
Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022.
The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 24 | -0.52 Increased by +23.53% | -0.57 Increased by +8.77% |
| Mar 28, 24 | -0.52 Increased by +67.70% | -0.41 Decreased by -26.83% |
| Nov 14, 23 | -0.37 Increased by +57.47% | -0.66 Increased by +43.94% |
| Aug 10, 23 | -0.61 Increased by +29.89% | -0.70 Increased by +12.86% |
| May 17, 23 | -0.68 Increased by +62.64% | -0.66 Decreased by -3.03% |
| Mar 30, 23 | -1.61 Increased by +55.52% | -0.85 Decreased by -89.41% |
| Nov 14, 22 | -0.87 Increased by +3.33% | -0.81 Decreased by -7.41% |
| Aug 15, 22 | -0.87 Increased by +3.33% | -1.12 Increased by +22.32% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 0.00 Decreased by N/A% | -4.93 M Increased by +93.20% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 7.05 M Increased by +5.54 K% | -4.89 M Increased by +81.63% | Decreased by -69.33% Increased by +99.67% |
| Sep 30, 23 | 0.00 Decreased by -100.00% | -3.48 M Increased by +43.21% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -5.56 M Increased by +8.98% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by -100.00% | -72.49 M Decreased by -379.86% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 125.00 K Increased by 0.00% | -26.61 M Decreased by -530.46% | Decreased by -21.29 K% Decreased by -530.46% |
| Sep 30, 22 | 125.00 K Increased by 0.00% | -6.12 M Decreased by -13.15% | Decreased by -4.90 K% Decreased by -13.15% |
| Jun 30, 22 | 125.00 K Increased by 0.00% | -6.11 M Decreased by -12.10% | Decreased by -4.89 K% Decreased by -12.10% |